Mithra Pharmaceuticals « Terug naar discussie overzicht

Mithra in 2018 - Erop of eronder

2.399 Posts, Pagina: « 1 2 3 4 5 6 ... 66 67 68 69 70 71 72 73 74 75 76 ... 116 117 118 119 120 » | Laatste
Money$Love
0
[verwijderd]
0
quote:

aossa schreef op 19 juli 2018 10:54:

Wat scheelt er met Esterella vandaag, heeft ze haar loeten?

www.youtube.com/watch?v=We7dLT1aSWo
tja, mensen die verkopen en voor snelle winst bij Gala gaan vermoed ik?
[verwijderd]
0
quote:

GalapaGeer schreef op 19 juli 2018 10:43:

Bedoeld voor het Gala draadje neem ik aan? :)
Nee bedoeld voor het Mithra draadje
[verwijderd]
0
De communicerende vaten.

Blijkt dat La Esterella s morgens nogal dikwijls met het verkeerde been uit bed stapt.

Maar des avonds voor het slapengaan op tijd haar beste vorm weer vindt.

[verwijderd]
1
quote:

Mopperaar schreef op 19 juli 2018 11:38:

De communicerende vaten.

Blijkt dat La Esterella s morgens nogal dikwijls met het verkeerde been uit bed stapt.

Maar des avonds voor het slapengaan op tijd haar beste vorm weer vindt.

haha, maar vanavond zie ik ze in de min eindigen, teveel in te halen

we'll see
[verwijderd]
0
[verwijderd]
2
quote:

Money$Love schreef op 19 juli 2018 14:06:

@mopperaar
Ik hoop dat het geen week duurt!
Als ge ouder bent dan 55 vindt ge da niet erg
JR von P
0
MITHRA OBTAINS FIRST MARKETING AUTHORIZATION FOR MYRING™ IN EUROPE
? Marketing authorization allows for launch of Myring™ in the United Kingdom
? Additional marketing authorizations expected in the near future
? Mithra to produce Myring™ at its CDMO2
Liège, Belgium, 20 July 2018 – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s
Health, today announces that the company obtained its first marketing authorization (MA) for
Myring™
1
in the UK, following approval by the MHRA2
. Myring™ is Mithra’s contraceptive vaginal ring
made of ethylene vinyl acetate copolymers (EVA) and is developed to be fully bioequivalent to Merck’s
Nuvaring®. In April 2018, Nuvaring® went off patent in both the US and Europe. In the UK, which is a
market worth approximately EUR 1.2 million3
, no generic competition exists as of yet.
Under the same decentralized procedure, in coming months, additional MA’s should be received for
Croatia, Hungary, the Czech Republic, Poland, Latvia, Slovakia, and Slovenia, with further MA’s
expected in Europe as well as the US later this year and early 2019.
François Fornieri, CEO Mithra Women’s Health: “We are very pleased to obtain the first marketing
authorization for Myring™. This is a great achievement for our team, highlighting our expertise in
polymer technology and the manufacturing capabilities at our state-of-the-art CDMO facility. We are
confident to receive MA’s in additional territories, including for the key US market, later this year or
early 2019, and look forward to producing Myring™ for our partners at our CDMO.”
*******
About Myring™
Myring™ is developed to be a generic of Nuvaring® vaginal ring. Nuvaring®’s patent expired in April
2018 both in the US and in EU. Myring™ (etonogestrel/ethinyl estradiol vaginal ring) is a nonbiodegradable,
flexible, transparent, combination contraceptive vaginal ring, with an outer diameter
of 54 mm and a cross-sectional diameter of 4 mm. It is made of ethylene vinylacetate copolymers, and
contains 11.7 mg etonogestrel and 2.7 mg ethinyl estradiol. When placed in the vagina, each ring
releases, in line with the originator (Nuvaring®), on average 0.120 mg/day of etonogestrel and
0.015 mg/day of ethinyl estradiol over a three-week period of use. The ring is to remain in place
continuously for three weeks. It is removed for a one-week break, during which a withdrawal bleed
usually occurs. A new ring is inserted one week after the last ring was removed.

1 Myring™ will be marketed under a different brand name in the UK.
2 Medicines and Healthcare products Regulatory Agency
3 CAGR (2013-2017): +6.6%
PRESS RELEASE
investors.mithra.com - 2
For more information, please contact:
Investor Relations
Sofie Van Gijsel
IRO & VP of Strategy
+32 485 19 14 15
investorrelations@mithra.com
About Mithra
Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in women's health, with a
particular focus on fertility, contraception and menopause. Mithra's goal is to develop new and
improved products that meet women's needs for better safety and convenience. Its two lead
development candidates - a fifth generation oral contraceptive, Estelle®, and a next generation
hormone therapy, Donesta®- are built on Mithra's unique natural estrogen platform, E4 (Estetrol).
Mithra also develops, manufactures and markets complex therapeutics and offers partners a
complete spectrum of research, development and specialist manufacturing at its Mithra CDMO.
Mithra was founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof.
Dr. Jean-Michel Foidart and is headquartered in Liège, Belgium. Further information can be found at:
www.mithra.com
[verwijderd]
0
Is een peanutsachievement maar peanuts feeds an elephant.

Beleggers zitten nu op grote deal te ge wachten voor verdeling van estelle/donests. Denk dat mithra beleggers gisteren gefrustreerd waren omdat galapagos wel iets gelijksaardig deed.

Hopelijk een groen tapijtje vandaag na de rode menestruatieflauwte van gisteren.
[verwijderd]
0
quote:

FilipVanderAa schreef op 20 juli 2018 11:34:

Ik hoop en denk dat ze bedoelen 1,2 miljard euro :)
nee hoor, 1,2 million ; t' is nog niet het pilletje he :-)
de tuinman
0
quote:

Elvisfan schreef op 20 juli 2018 13:42:

[...]

nee hoor, 1,2 million ; t' is nog niet het pilletje he :-)
Maar dat is alleen UK, toch?
de tuinman
0
Maar moet Mithra nu toestemming krijgen per land om hun ring te verkopen? Daar is toch het EMA voor?
2.399 Posts, Pagina: « 1 2 3 4 5 6 ... 66 67 68 69 70 71 72 73 74 75 76 ... 116 117 118 119 120 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 26 apr 2024 17:35
Koers 0,216
Verschil -0,004 (-1,82%)
Hoog 0,225
Laag 0,216
Volume 82.336
Volume gemiddeld 382.106
Volume gisteren 113.992

EU stocks, real time, by Cboe Europe Ltd.; Other, Euronext & US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront